– Prima doză de vaccin anti-COVID19 dezvoltat de Pfizer este eficientă în proporţie de 85%, se arată într-un studiu realizat în rândul personalului medical de la un spital israelian, alimentând dezbaterile cu privire la schema recomandată de două doze, relatează vineri Reuters.
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2012/04/pfizer_0123_36610900.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2021/01/vaccine_53622600-643x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/11/screenshot_2020_09_16_at_09_43_56_79529400-752x420.png)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2017/02/istock_000011686797small_58501300-562x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2012/04/pfizer_0123_36610900.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/11/pfizer_vaccin__8868785_47494100-800x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/12/pfizer_biontech_covid_19_vaccine_2020_c_cropped_09724400-326x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/11/vaccination_1024x683_47930700-630x420.jpeg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/11/vaccine_770_58361900-629x420.jpg)
:format(webp):quality(92)/https://www.economica.net/wp-content/uploads/2020/10/covid_19_vaccine_1500x856_75812500-840x420.jpg)
